HomeCompareLVSDF vs ABBV

LVSDF vs ABBV: Dividend Comparison 2026

LVSDF yields 4000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVSDF wins by $206.67M in total portfolio value
10 years
LVSDF
LVSDF
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$206.77M
Annual income
$4,025,981.19
Full LVSDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LVSDF vs ABBV

📍 LVSDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVSDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVSDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LVSDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVSDF
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,422,084.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LVSDF beats the other by $3,401,028.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVSDF + ABBV for your $10,000?

LVSDF: 50%ABBV: 50%
100% ABBV50/50100% LVSDF
Portfolio after 10yr
$103.44M
Annual income
$2,025,376.48/yr
Blended yield
1.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LVSDF
No analyst data
Altman Z
-0.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVSDF buys
0
ABBV buys
0
No recent congressional trades found for LVSDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVSDFABBV
Forward yield4000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$206.77M$102.3K
Annual income after 10y$4,025,981.19$24,771.77
Total dividends collected$154.59M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LVSDF vs ABBV ($10,000, DRIP)

YearLVSDF PortfolioLVSDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$210,700$200,000.00$11,550$430.00+$199.2KLVSDF
2$2,194,608$1,969,158.88$13,472$627.96+$2.18MLVSDF
3$11,932,508$9,584,277.57$15,906$926.08+$11.92MLVSDF
4$37,118,986$24,351,202.37$19,071$1,382.55+$37.10MLVSDF
5$75,114,686$35,397,370.81$23,302$2,095.81+$75.09MLVSDF
6$113,845,047$33,472,333.01$29,150$3,237.93+$113.82MLVSDF
7$145,520,376$23,706,175.51$37,536$5,121.41+$145.48MLVSDF
8$169,866,611$14,159,808.80$50,079$8,338.38+$169.82MLVSDF
9$189,481,017$7,723,743.28$69,753$14,065.80+$189.41MLVSDF
10$206,770,669$4,025,981.19$102,337$24,771.77+$206.67MLVSDF

LVSDF vs ABBV: Complete Analysis 2026

LVSDFStock

Lai Sun Development Company Limited, together with its subsidiaries, invests in, develops, leases, and sells real estate properties in Hong Kong, Mainland China, Macau, the United Kingdom, Vietnam, and internationally. It operates through Property Development and Sales; Property Investment; Hotel Operation; Restaurant and F&B Product Sales Operations; Media and Entertainment; Film and TV Program; Cinema Operation; Theme Park Operation; and Others segments. The company also invests in, develops, operates in, and manages cultural, leisure, entertainment, and related facilities; operates hotels and restaurants; and provides management and consultancy services to hotels, serviced apartments, and restaurants. In addition, it engages in the development, operation, and investment of media and entertainment events; cinema operations; golf apparel retailing; and music production and distribution, as well as provision of related advertising services. Further, the company invests in, produces, licenses, and distributes television programs, films, and video format products. Additionally, the company offers property management, real estate agency, leasing agency, performance agency, and building services; and luxury yachts brokerage, charter, marketing, management, and crew placement services; and finance and treasury services. It also provides artiste management services; sells albums; distributes and licenses music and film rights; and trades in gaming products. In addition, the company distributes movie digital video discs and Blu-ray discs. Further, it engages in the film library management; provision of video duplication services; translating and subtitling of television programs; and selling of beverage products. The company was incorporated in 1959 and is headquartered in Central, Hong Kong. Lai Sun Development Company Limited is a subsidiary of Lai Sun Garment (International) Limited.

Full LVSDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LVSDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVSDF vs SCHDLVSDF vs JEPILVSDF vs OLVSDF vs KOLVSDF vs MAINLVSDF vs JNJLVSDF vs MRKLVSDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.